



10TH ANNUAL MEETING
Stockholm • 2026



10th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, August 28 to Sunday, August 30, 2026

Stockholm, Sweden

Final Programme



Invitation 10th Meeting – Stockholm

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to welcome you to the 10th Annual EHTG Meeting, taking place from August 28-30, 2026 in Stockholm.

Join us for the full program focusing on new technologies, emerging treatments and other developments in the fields of genetics, gastroenterology, oncology, endoscopy and surgery in hereditary gastrointestinal tumours.

The program will feature cutting-edge and controversial topics, expert discussions and debates, and valuable insights from both clinical and patient perspectives. Together, we will explore advances in precision medicine, prevention, surveillance, guideline development, and collaborative European research initiatives.

Beyond the scientific sessions, this year's meeting offers a unique opportunity to strengthen collaboration within our growing international community. We look forward to inspiring discussions, new connections, and shaping the future of hereditary tumour research and care together.

Please visit www.ehtg.org for more information and contact gs007@ehtg.org for organizational queries.

We are excited to welcome you to Stockholm at the end of August!

Sincerely yours,
EHTG Programme Committee and Board Members

Organisation

Board Members:
Chair: Toni Seppälä
Vice-Chair: Gabriela Möslein
General Secretary: Kelly Kohut
Treasurer: Elizabeth Half
Y-EHTG: Maria Rasmussen
Communications Chair: Patrick Benusiglio
Programme Chair: Maartje Nielsen
Education: Neil Ryan
Nurses/Genetic Counseling: Mechelle Loughrey

Programme Committee:
 Maartje Nielsen, The Netherlands
 Ann-Sofie Backman, Sweden
 (Programme Directors)
 Patrick Benusiglio, France
 Kaisa Fritzell, Sweden
 Elizabeth Half, Israel
 Kelly Kohut, United Kingdom
 Florian Kühn, Germany
 Annica Lindblom, Sweden
 David Ljungman, Sweden
 Matthias Löhr, Sweden
 Maria Rasmussen, Denmark

Congress Organisation/ Secretariat:
 Gabriele Sponholz
gs007@ehtg.org
 +49 160 8459502
 65207 Wiesbaden, Germany



Location:
 ERSTA Conference Centre
 Erstagatan 1K
 Södermalm, Stockholm
 +46 (0)8-714 63 41

Registration and Registration Fee:
 See online via www.ehtg.org

Certification:
 The event has been certified by UEMS/ EACCME. Credit points to follow soon, see website

Content

Invitation	2
Organisation	3
Meeting Overview Friday	6
Meeting Overview Saturday	8-10
Meeting Overview Sunday	11
Day 1 – Friday, September 28	
Site Visit Karolinska University Hospital	12
Y-EHTG Come together	12
Registration	12
Welcome to EHTG 2026	12
New Developments in Preventive Measures and Treatment Options	12-13
Novel Approaches to Genetic Counselling	13-14
A paradigm shift in rectal cancer management	14-15
Scientific Speed-Dating	15-16
Welcome Reception	16
Young EHTG – Meet & Great	16
Day 2 - Saturday 29	
ILSD Business Meeting	18
Secondary Use of Cancer Health Data in Europe	18
New Hereditary Gastrointestinal Cancer Syndromes / Genetics Session	19
Hereditary Colorectal Cancer: Mucosal Immunology and Vaccines	20
Rare cancers in Hereditary Gastrointestinal Syndromes. Clinical and Molecular Session-	20-21
Chemoprevention	21-22
Dynamic EHTG guidelines – Controversial and Ethical Issues in Development of Guidelines in Hereditary Syndromes	22
Interactive Discussion & Thematic Debate: “What Do We Lack, What Do We Need, and Who Should Lead?”	23

Content

Social Event: Junibacken, Djurgården	23
Parallel Working Groups	
Research Collaborative Workshop: Polyposis Syndromes	24
Endoscopy Session** FAP and Lynch	25
Day 3 - Sunday 30	
EHTG Business Meeting	26
Changes in Population Screening and the Consequences for Patients with an Increased Risk	26
Ideas for the Future and New Developments	26-27
Heading Forward Together. Summary, Conclusion and Final Remarks	27
Faculty	28-33
Sponsors	34
Imprint	35

Day 1 – Friday, August 28

Time	Event – Room Bring/Norrby
08:30-10:00	Site Visit Karolinska University Hospital, Solna (limited spaces)
09:30-11:00	Y-EHTG Come together at ERSTA Conference center
11:00-11:30	Registration / Coffee
11:30-11:45	Welcome to EHTG 2026
11:45-12:15	New Developments in Preventive Measures and Treatment Options
12:15-13:00	New Developments in Preventive Measures and Treatment Options in Hereditary Forms of (GI) Tumors
13:00-14:00	Lunch Break
14:00-15:30	Novel Approaches to Genetic Counselling
15:30-16:00	Coffee Break
16:00-17:30	A Paradigm Shift in Rectal Cancer Management
17:30-18:30	Scientific Speed-Dating and Poster Presentation
18:30-20:00	Welcome Reception with a View – ERSTA Conference Centre
20:00	Young EHTG – Meet & Great

Notes

Meeting Overview

Day 2 – Saturday, August 29

Time Event – Room Bring/Norby

08:00-08:30 ILSD Business meeting

08:30-09:30 **Secondary use of cancer health data in Europe**
Managing hereditary cancer registries
Study proposals /abstract ILSD/other EU collaborations

09:30-10:00 Coffee Break

10:00-11:15 **New hereditary gastrointestinal cancer syndromes**
Genetics session

11:15-12:00 **Hereditary Colorectal Cancer: Mucosal Immunology and Vaccines**
Vaccination in Lynch Syndrome: Clinical Feasibility and Promising Early Outcomes

12:00-13:00 Lunch

13:00-14:30 **Rare Cancers in Hereditary Gastrointestinal Syndromes**
Clinical and molecular session
Infrequent cancers in Lynch syndrome, with a focus on glioma

14:30-15:00 Coffee Break

Meeting Overview

Day 2 – Saturday, August 29

Parallel Working Groups

Time Event – Cederschiöldsalen

08:30-10:00 **Research Collaborative Workshop: Polyposis Syndromes**
Patient Perspectives: Do we really know how patients are feeling, and can we acquire that knowledge with patient reported data?

10:00-12:00 **Endoscopy Session** FAP and Lynch**
Management of Duodenal Polyposis in FAP Including Surveillance and Management of Gastric Lesions
Endoscopic Management of Polyposis in FAP, Lower GI.
Endoscopic Surveillance in Lynch syndrome

12:00-13:00 Lunch



Meeting Overview

Day 2 – Saturday, August 29

Time	Event – Room Bring/Norrbý
15:00-15:50	Chemoprevention Aspirin in Lynch Syndrome – Standard of Care or Premature?
15:50-16:00	Short Break
16:00-16:30	Dynamic EHTG guidelines – Controversial and Ethical Issues in Development of Guidelines in Hereditary Syndromes
16:30-17:30	Interactive Discussion & Thematic Debate: “What Do We Lack, What Do We Need, and Who Should Lead?”
18:15	Transfer to Dinner at Djurgården
19:30	Congress Dinner at Junibacken, Djurgården



Meeting Overview

Day 3 – Sunday, August 30

Time	Event – Room Bring/Norrbý
08:30-09:00	EHTG Business meeting
09:00-10:00	Changes in Population Screening and the Consequences for Patients with an Increased Risk The Swedish Cancer Strategy, Screening and Surveillance
10:00-10:30	Coffee Break
10:30-11:45	Ideas for the Future and New Developments
11:45-12:15	Heading forward together. Summary, conclusion and final remarks

+

X

=



Scientific Programme

Day 1 – Friday, August 28

08:30-10:00 Site Visit Karolinska University Hospital, Solna (limited space)

9:30-11:00 Y-EHTG Come together at ERSTA Conference center

11:00-11:30 Registration / Coffee

11:30-11:45 **Welcome to EHTG 2026**
Ann-Sofie Backman, Sweden
Maartje Nielsen, The Netherlands
Toni Seppälä, Finland

11:45-13:00 **New Developments in Preventive Measures and Treatment Options**
Chairs: Matthias Löhr, Sweden
Emma Tham, Sweden
Alethea Tang, United Kingdom

11:45-12:15 **Precision Medicine in Hereditary Gastrointestinal Tumors**
Richard Rosenquist Brandell, Sweden

12:15-13:00 **New Developments in Preventive Measures and Treatment Options in Hereditary Forms of (GI) Tumors**

ABSTRACTS

8'+2' **Engineering the Two-in-one Hit Mechanism of Colorectal Carcinogenesis in Normal Colon Organoids Derived from Lynch syndrome Carriers**
Aysel Ahadova, Germany

8'+2' **Somatic CTNNB1 Mutations as a Positive Predictor of Lynch syndrome**
Aysel Ahadova, Germany

Scientific Programme

Day 1 – Friday, August 28

8'+2' **Cell-Free DNA in Hereditary and High-Risk Malignancies 2 (CHARM2): A Randomized Controlled Trial for Early Cancer Detection**
Sarah Ridd, Canada

8'+2' **Epigenetic Treatment of Lynch Syndrome-associated Colorectal Carcinoma and BRAF-mutant Colorectal Carcinoma**
Anna Scheßl, Germany

13:00-14:00 **Lunch Break**

14:00-15:30 **Novel Approaches to Genetic Counselling**
Chairs: Anna Rosen, Sweden
Kaisa Fritzell, Sweden
Sanne Baiwa ten Broeke, The Netherlands

14:00-14:20 **Implementing Mainstream Germline Genetic Testing in Breast Cancer**
Svetlana Bajalica Lagercrantz, Sweden

14:20-14:40 **Artificial Intelligence and Genetic Counseling in Hereditary Cancer Syndromes**
Elen Siglen, Norway

14:40-15:30 ABSTRACTS

8'+2' **Genetic Counselling Regarding Recessive Syndromes Associated with Cancer Predisposing Genes: A Consensus on Shared Decision-Making**
Judith Sanz Buxo, Spain

8'+2' **Exploring Quality of Life, Illness Representations, Coping Strategies, and Needs in Patients with APC-Related Desmoid-Type Fibromatosis**
Bianca Scacciati, Italy

8'+2' **Frequency of Second Hits in Normal Lynch syndrome Colonic Mucosa: a Paired Spatial Mapping Pilot Comparing MMR-deficient Crypts With a Clonal Reference Marker**
Leon Marin Grez, Germany

Scientific Programme

Day 1 – Friday, August 28

8'+2' **Implementing a Canadian Population Genomic Screening Study for Hereditary Cancers**
Laura Redondo, Canada

8'+2' **Diagnostic Value of Long-Read Sequencing in Unexplained Mismatch Repair Deficient MMR) Cancer Cases**
Sanne Bajwa-ten Broeke, The Netherlands

15.30-16.00 **Coffee Break**

16:00-17:30 **A Paradigm Shift in Rectal Cancer Management**

*Chairs: David Ljungman, Sweden
Toni Seppälä, Finland
Gustav Silander, Sweden*

16:00-16:20 **The Surgeon's Perspective: Organ Preservation and Watch and Wait in Rectal Cancer**
Per Nilsson, Sweden

16:20-16:40 **The Oncologist's Perspective Management of dMMR Rectal Cancer (Consequences for Patient with Hereditary Cancer Lynch syndrome)**
Mef Nilbert, Sweden

16:40-17:30 **Greetings and welcome from Ersta hospital CEO, an organizational perspective**
Sara Lindholm Larsson, Sweden

ABSTRACTS

6'+2' **Incidental Colorectal Cancer in APC-Mutated Familial Adenomatous Polyposis: Implications for Surgical Strategy**
Emanuele Rausa, Italy

6'+2' **Surgery for MUTYH-Associated Polyposis: Surgical Management and Outcomes in a Single-Centre Cohort of 171 Patients**
Alberto Gorini, Italy

Scientific Programme

Day 1 – Friday, August 28

6'+2' **Upper Gastrointestinal Neoplasia Detection in Lynch Syndrome: High Yield of Esophagogastroduodenoscopy Surveillance**
Elizabeth Half, Israel

6'+2' **Association of Prior Cancer Burden with Cancer Incidence in MLH1 and MSH2 Lynch syndrome Carriers Undergoing Colonoscopy Surveillance**
Kalle Hokkanen, Finland

6'+2' **High Prevalence of Lynch syndrome Identified via Clinical Whole-Genome Sequencing in a Large Swedish Colon Cancer Cohort**
Kristina Lagerstedt Robinson, Sweden

17:30-18:30 **Scientific Speed-Dating and Poster Presentation (BIBLIOTEK)**
Y-EHTG

5'+2' **A Truncating NLRC4 Gene Variant Predisposing to Familial Colorectal Carcinoma**
Taina Nieminen, Finland

5'+2' **Not All Deficiencies Are Created Equal: Clinical Landscapes and Immunotherapy Outcomes in Mismatch Repair Deficient Colon Cancer**
Sofia Silva, Spain

5'+2' **Endometrial Cancer in Lynch Syndrome: Age at Diagnosis and Family History in a US Genetic Testing Registry**
Laura Wollborn, USA

5'+2' **Personalised Risk Stratification in Colorectal Cancer Screening: Integrating Germline Genetic Predisposition and Clinical Data in a Danish Population-Based Screening Cohort**
Heidi Brinch, Denmark

5'+2' **Attenuated, Variable Phenotype in a Family with Peutz-Jeghers Syndrome due to a Splice Site Variant with Reduced Splicing Efficiency**
Laura Grohs, Germany

Day 1 – Friday, August 28

Endoscopic Communication and Risk Interpretation in Hereditary Colorectal Cancer: the ENCOUNTER Study – A Qualitative Interview Study of Endoscopists

Alexander Frank, Sweden

Barriers to Implementation of Hereditary Gastrointestinal Cancer Screening in Low-Resource Health Systems: a Narrative Review

20:00 Young EHTG – Meet & Great

EVENING for free disposition

Scientific Programme

Day 2 – Saturday, August 29

08:00-08:30 ILSD Business Meeting
Chairs: Christina Therkildsen, Denmark
Gabriel Capella, Spain

08:30-09:30 Secondary Use of Cancer Health Data in Europe
Chairs: Johannes Blom, Sweden
Asaf Maoz, USA
Rakefet Chen-Shtoyerman, Israel

08:30-08:50 Managing hereditary cancer registries
Christina Therkildsen, Denmark
John Gásdal Karstensen, Denmark

08:50-09:30 Study Proposals / Abstracts – ILSD / other EU Collaborations

8'+2' Extrapolating the CanRisk Framework to Hereditary Colorectal Cancer (CRC) and Polyposis: A Collaborative Proposal
Sanne Bajwa-ten Broeke, The Netherlands

8'+2' Possible Period Bias in Cancer Incidence Rates in the Prospective Lynch syndrome Database Following the Introduction of Amsterdam Criteria
Kalle Hokkanen, Finland

8'+2' Familial Colorectal Cancer History and Participation in Organised Stool-Based Colorectal Cancer Screening in Sweden: The FENCE Register-Linked Cohort Study
Alexander Frank, Sweden

8'+2' Novel methodologies for Lynch syndrome registry research in Finland
Piia Takabe, Finland

09:30-10:00 Coffee Break

Scientific Programme

Day 2 – Saturday, August 29

10:00-11:15 New Hereditary Gastrointestinal Cancer Syndromes / Genetics Session
Chairs: Ingrid Winship, Australia
Kristina Lagerstedt-Robinson, Sweden
Romy Walker, Australia

ABSTRACTS

8'+2' A Founder ATM Pathogenic Variant Among Ashkenazi Jews: Cancer Risk and Clinical Implications
Yael Goldberg, Canada

8'+2' Early-Onset Cancers Without Familial Aggregation Reveal Significant Germline Pathogenic Variants
Litika Vermani, India

8'+2' Germline KIT Mutation in a Norwegian Family with GIST: Predictive Testing and Follow up
Vibeke Wethe, Norway

8'+2' Breast Cancer Phenotypes in Carriers of Pathogenic POT1 Variants
Tal Hadar, Israel

8'+2' Cumulative Incidence of First Cancer Severely Underestimates Lifetime Cancer Burden in MLH1 and MSH2, but not in MSH6 or PMS2, Lynch syndrome Carriers
Kalle Hokkanen, Finland

8'+2' Timing of Germline Testing and Stage of Colorectal and Endometrial Cancer in Lynch syndrome Carriers: a Retrospective Cohort Study Using Linked Electronic Health Records
Helen White, United Kingdom

8'+2' The Genetic Landscape of Colon Cancer Susceptibility Genes Among the Israeli Arab Population
Yael Goldberg, Israel

Scientific Programme

Day 2 – Saturday, August 29

11:15-12:00 Hereditary Colorectal Cancer: Mucosal Immunology and Vaccines

*Chairs: Aysel Ahadova, Germany
Matthias Kloor, Germany
Hugo Montemont, Germany*

11:15-11:35 Vaccination in Lynch syndrome: Clinical Feasibility and Promising Early Outcomes

Jolanda de Vries, The Netherlands

11:35-12:00 ABSTRACTS

6'+2' Clinicopathological and Molecular Characteristics of Double Somatic DNA Mismatch Repair Gene Mutation Cases: a Systematic Review and Meta-Analysis

Romy Walker, Australia

6'+2' The Immunological Environment and Tumor Evasion in Lynch syndrome-associated Urothelial Tumors

Maria Rasmussen, Denmark

6'+2' Comprehensive Peripheral Immunophenotyping Analyses Reveal Systemic Immune Activation in Hereditary Cancer Predisposition Syndromes

Vince Kornél Grolmusz, Hungary

12:00-13:00 Lunch Break

13:00-14:30 Rare Cancers in Hereditary Gastrointestinal Syndromes. Clinical and Molecular Session

*Chairs: Elizabeth Half, Israel
Yael Goldberg, Israel
Henriett Butz, Hungary*

13:00-13:20 Infrequent Cancers in Lynch syndrome, with a Focus on Glioma

Patrick Benusiglio, France

Scientific Programme

Day 2 – Saturday, August 29

13:20-14:30 ABSTRACTS

6'+2' Higher-than-expected Prevalence of Germline PTEN Variants Reveals Attenuated PTEN Hamartoma Tumour Syndrome Phenotypes in Cancer Patients

Henriett Butz, Hungary

6'+2' Integrative Analysis of Plasma cfDNA Features in Endometrial Cancer and Benign Endometrial Pathology

Jakub Styk, Slovakia

6'+2' Risk Factors for Gastric Cancer in Patients with Lynch syndrome: A Systematic Review and Meta-analysis

Daniela Silva, Portugal

6'+2' Overall Survival of Individuals with Pancreatic Adenocarcinoma Harboring Pathogenic Germline Variants in BRCA1, BRCA2, PALB2 or ATM

Asaf Maoz, USA

6'+2' Non-Invasive Urine Based Detection of Mismatch Repair Deficiency in Endometrial Cancer

Rachel Phelps, United Kingdom

6'+2' Mismatched Lynch Syndrome Diagnostics; Suboptimal Attrition Challenges Benefit from Universal Screening for Defective Mismatch Repair in Colorectal Cancer

Lovisa Lesand, Sweden

14:30-15:00 Coffee Break

15:00-15:50 Chemoprevention

*Chairs: Ann-Sofie Backman, Sweden
Maria Rasmussen, Denmark
Kelly Kohut, United Kingdom*

Scientific Programme

Day 2 – Saturday, August 29

- 15:00-15:30 **Aspirin in Lynch syndrome – Standard of Care or Premature?**
Tim Bishop, United Kingdom
Peter Bauerfeind, Switzerland
- 15:30-15:50 **Abstract/Proposal/Ongoing Studies – Preventive Medicine**
- 6'+2' **Feasibility and Preliminary Results of an Electronic Dietary Assessment eHealth Intervention in Patients at Increased Hereditary/Genetic Cancer Risk**
Michael Hall, USA
- 6'+2' **How are Patients with Lynch syndrome Informed about Aspirin Chemoprevention by Genetic Counselors, and what Factors Influence Communication Behaviors?**
Michael Hall, USA
- 5' **Space for study proposal/Discussion**
- 15:50-16:00 **Short Break**
- 16:00-16:30 **Dynamic EHTG Guidelines – Controversial and Ethical Issues in Development of Guidelines in Hereditary Syndromes**
Chairs: Maartje Nielsen, The Netherlands
Kaisa Fritzell, Sweden
Litika Vermani, India
- 16:00-16:15 **Overview of Existing Guidelines – Which Guidelines currently exist? – Where do they overlap or conflict?**
Maartje Nielsen, The Netherlands
- 16:15-16:30 **How Guidelines Are Made – The UK Approach (example MUTYH testing guideline)**
Terri McVeigh, United Kingdom

Scientific Programme

Day 2 – Saturday, August 29

- 16:30-17:30 **Interactive Discussion & Thematic Debate: “What Do We Lack, What Do We Need, and Who Should Lead?”**

Chairs: Maartje Nielsen, The Netherlands
Kaisa Fritzell, Sweden

Maartje Nielsen, The Netherlands
Kaisa, Fritzell, Sweden
Gabriela Möslin Germany
Anna Rosen, Sweden
Kelly Kohut, United Kingdom
Terri McVeigh, United Kingdom
Gustav Silander, Sweden

- 18:15 **Transfer to Dinner at Djurgården**

- 19:30 **Social Event: Junibacken, Djurgården**

Scientific Programme

Day 2 – Saturday, August 29

Parallel Working Groups – Cederschiöldsalen

- 08:30-10:00 **Research Collaborative Workshop: Polyposis Syndromes**
Chair: *Kaisa Fritzell*
- 08:30-08:40 **Brief Description on PROM and PREM – How to use and what to do with the results.**
Kaisa Fritzell
- 08:40-08:55 **Presentation of the Swedish aAdaptation of the Genetic Counseling Outcome Scale-24 (GCOS-24)**
Rebecka Pestoff, Sweden
- 08:55-09:10 **Experience of using GCOS-24 in the Clinic**
Lisa Åkerman, Sweden
Ann Lindén, Sweden
- 09:10-09:20 **Results from the Study: “Mental- and Physical Health, and General Well-being in Patients with Polyposis Syndromes: a Scoping Review**
Sophie Walton Bernstedt, Sweden
- 09:20-09:30 **Presentation of a Research Project Aiming to Develop and Implementing Polyposis Syndrome Specific PROMs in Sweden – Looking for Collaborators**
Kaisa Fritzell, Sweden
- 09:30-09:40 **Patients’ Perspective on what is Important to Measure when Having a Polyposis Syndrome?**
Emil Willman, Sweden
Samantha Hermannsson, Sweden
- 09:40-10:00 **General Discussion: Do we Need to Collect Data in a Structured Way with PROM/PREM?**
Georgina Hoffmann, Germany
Nicola Reents, Germany

Scientific Programme

Day 2 – Saturday, August 29

Parallel Working Groups – Cederschiöldsalen

- 10:00-12:00 **Endoscopy Session** FAP and Lynch**
Chair: *Maria Elmberg, Sweden*
Elizabeth Half, Israel
Peter Thelin-Schmidt, Sweden
- 10:00-10:15 **Endoscopic Management of duodenal polyposis and gastric lesions in FAP. What to remove, when to remove and how should it be done?**
John Gásdal Karstensen, Denmark
- 10:15-10:25 **When the endoscopist had enough, aspects of surgical management in duodenal polyposis and gastric lesions**
NN
- 10:30-10:40 **Endoscopic management of polyposis in FAP, lower GI**
John Gasdal Karstensen, Denmark
- 10:40-11:00 **Surgical aspects in FAP, lower GI, where are we now?**
David Ljungman, Sweden
- 11:05-11:15 **Upper endoscopic Surveillance in Lynch syndrome, time to individualize?**
Lars Joachim Lindberg, Denmark
- 11:15-11:25 **Lower endoscopic surveillance in Lynch syndrome, aspects of quality, frequency and organization**
Lars Joachim Lindberg, Denmark
- 10:25-11:40 **Fullthickness resection eFTR in hereditary cancer**
Peter Bauerfeind, Switzerland
- 11:40-11:50 **The surgeons role in Lynch syndrome**
David Ljungman, Sweden
- 11:50-12:00 **Discussion**
ALL ABOVE

Scientific Programme

Day 3 – Sunday, August 30

08:30-09:00 **EHTG Business Meeting**
Chairs: Toni Seppälä, Finland
Gabriela Moeslein, Germany

09:00-10:00 **Changes in Population Screening and the Consequences for Patients with an Increased Risk**
Chairs: Johannes Blom, Sweden
Kalle Hokkanen, Finland

09:00-09:10 **The Swedish Cancer Strategy, Screening and Surveillance**
Mef Nilbert, Sweden

09:10-09:20 **The Finnish cancer strategy, screening and surveillance**
Timo Nykopp, Finland

09:20-09:30 **Discussion**

09:30-10:00 ABSTRACTS

8'+2' **Evaluation of Upper Gastrointestinal Tract Surveillance in Individuals with Lynch syndrome (EARLY): An International, Multicenter Registry**
Katrin van Beekum, Germany

8'+2' **Reflex CRC Initiative - Advancing Colorectal Cancer Care through Comprehensive Genetic Testing**
Christoforos Pappas, Sweden

8'+2' **Pap Smear Liquid Biopsy Enables Non-invasive Detection of Microsatellite Instability in Endometrial Cancer**
Alexandre Perrier, France

10:00-10:30 **Coffee Break**

10:30-11:45 **Ideas for the Future and New Developments**
Chairs: Sanne Bajwa-ten Broeke, The Netherlands
Patrick Benusiglio, France
Rachel Phelps, United Kingdom

Scientific Programme

Day 3 – Sunday, August 30

10:45-11:30 ABSTRACTS

8'+2' **Correlation of the Mismatch Repair-deficient Crypt foci Density with Clinical Patient Characteristics**
Hugo Montemont, Germany

8'+2' **Classification of MSH6 variants of uncertain significance (VUS) using high-throughput CRISPR functional analysis for improved precision genomic medicine**
Signe Grue Andreassen, Denmark

8'+2' **Histopathological, Epidemiological, and Molecular Profiling of PMS2 Lynch Syndrome Adenomas**
Katarina Andini, Netherlands

8'+2' **The Interplay Between Aging, Physical Activity and Immune Cells in Cancer Risk Regulation in Lynch syndrome**
Tiina Jokela, Finland

5' **Time for study proposal/late breaking abstract**

11:30-11:45 **Discussion**

11:45-12:15 **Heading Forward Together. Summary, Conclusion and Final Remarks**
Chairs: Toni Seppälä, Finland
Ann-Sofie Backman, Sweden
Maartje Nielsen, The Netherlands

Panel Discussion, with:
Annika Lindblom, Sweden
Aysel Ahadova, Germany
Yael Goldberg, Canada
David Ljungman, Sweden
Patrick Benusiglio, France
Maria Rasmussen, Denmark
Kaisa Fritzell, Sweden

12:30 **Farewell / Adjourn**
Toni Seppälä, Finland
Gabriela Mösllein, Germany

Faculty

Ahadova, Aysel p. 12, 20, 21, 27	Heidelberg University Hospital Heidelberg, Germany
Åkerman, Lisa p. 24	Sweden
Andini, Katarina p. 27	University Medical Centre Groningen Groningen, Netherlands
Andreassen, Signe Grue p. 13, 26	Rigshospitalet Copenhagen, Denmark
Backman, Ann-Sofie p. 12, 21, 27	Karolinska Institute Stockholm, Sweden
Bajalica Lagercrantz Svetlana p. 13	Karolinska Institute Stockholm, Sweden
Bajwa-ten Broeke, Sanne p. 13, 14, 18, 27	University Medical Center Groningen Groningen, The Netherlands
Bauerfeind, Peter p. 22	Hirslanden Hospital Luzern/Zürich, Switzerland
Benusiglio, Patrick p. 20, 27	Sorbonne, Hôpitaux Pitié-Salpêtrière Paris, France
Bishop, Tim p. 21	University of Leeds Leeds, United Kingdom
Blom, Johannes p. 18, 26	Karolinska Institute Stockholm, Sweden
Brinch, Heidi p. 15	Copenhagen University Hospital Copenhagen, Denmark
Butz, Henriett p. 20, 21	National Institute of Oncology Budapest, Hungary
Capella, Gabriel p. 18	Catalan Institute of Oncology IDIBELL Hospitalet de Llobregat, Spain
Chen-Shtoyerman, Rakefet p. 18	Kaplan Medical Center Rehovot, Israel
de Vries, Jolanda p. 20	RadboudUMC Nijmegen, The Netherlands

Faculty

Elmberg, Maria p. 25	Sweden
Frank, Alexander p. 16, 18	Karolinska Institute Stockholm, Sweden
Fritzell, Kaisa p. 13, 22, 23, 24, 27	Karolinska Institute Huddinge, Sweden
Goldberg, Yael p. 19, 20, 27	Rabin Medical Center Princess Margaret Hospital Toronto, Canada
Gorini, Alberto p. 14	Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
Grohs, Laura p. 15	University of Bonn, Medical Faculty Bonn, Germany
Grolmusz, Vince Kornél p. 20	National Institute of Oncology Budapest, Hungary
Hadar, Tal p. 19	Hadassah Medical Center Jerusalem, Israel
Half, Elizabeth p. 15, 20, 21, 25	Rambam Health Care Campus Haifa, Israel
Hall, Michael p. 22	Fox Chase Cancer Center Philadelphia, USA
Hermannsson, Samantha p. 24	Sweden
Hoffmann, Georgina p. 24	SemiColon Schorndorf, Germany
Hokkanen, Kalle p. 15, 18, 19, 26	Tampere University and Tays Cancer Centre Tampere, Finland
Jokela, Tiina p. 18	University of Jyväskylä Jyväskylä, Finland
Karstensen, John Gásdal p. 18, 25	Amager og Hvidovre Hospital Copenhagen, Denmark

Faculty

Kloor, Matthias p. 20	Heidelberg University Hospital Heidelberg, Germany
Kohut, Kelly p. 23	University of Exeter Medical School Exeter, United Kingdom
Lagerstedt Robinson, Kristina p. 15, 19	Karolinska Institute Sweden Stockholm, Sweden
Lesand, Lovisa p. 21	Lund University Lund, Sweden
Lindberg, Lars Joachim p. 24, 25	Hvidovre Hospital Copenhagen, Denmark
Lindblom, Annika p. 27	Karolinska Institute Stockholm, Sweden
Lindén, Ann p. 24	Stockholm, Sweden
Lindholm Larsson, Sara p. 14	Karolinska Institute Stockholm, Sweden
Ljungman, David p. 14, 27	Sahlgrenska University Hospital Göteborg, Sweden
Löhr, Matthias p. 12	Karolinska Institute Stockholm, Sweden
Maoz, Asaf p. 18, 21	Harvard Medical School, Dana-Farber Cancer Institute Boston M.A., USA
Marin Grez, Leon p. 14	University Hospital Heidelberg, Institute of Pathology Heidelberg, Germany
McVeigh, Terri p. 22, 23	Royal Marsden Hospital NHS Trust Lonen, United Kingdom
Möslein, Gabriela p. 23, 26	Evangelisches Bethesda Krankenhaus Duisburg, Germany
Montemont, Hugo p. 20, 27	University Hospital Heidelberg, Institute of Pathology Heidelberg, Germany

Faculty

Nielsen, Maartje p. 12, 22, 23, 27	Leiden University Medical Center Leiden, The Netherlands
Nieminen, Taina p. 15	University of Helsinki Helsinki, Finland
Nilbert, Mef p. 14, 26	Lund University Lund, Sweden
Nilsson, Per p. 14	Karolinska Institute Stockholm, Sweden
Nykopp, Timo p. 26	University of Eastern Finland Kuopio, Finland
Pappas, Christoforos p. 26	Karolinska Institutet, Department of Molecular Medicine and Surgery Stockholm, Sweden
Perrier, Alexandre p. 27	Sorbonne Université, INSERM Paris, France
Pestoff, Rebecka p. 24	Linköping, Sweden
Phelps, Rachel p. 27	Newcastle University Newcastle upon Tyne, United Kingdom
Rasmussen, Maria p. 20, 21, 27	Copenhagen University Hospital, The Danish HNPCC Register Copenhagen, Denmark
Rausa, Emanuele p. 14	Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
Redondo, Laura p. 14	Princess Margaret Cancer Centre, University Health Network Toronto, Canada
Reents, Nicola p. 24	SemiColon Moenchengladbach, Germany
Ridd, Sarah p. 13	Princess Margaret Cancer Centre, University Health Network Toronto, Canada
Rosen, Anna p. 13, 23	Umea University Umea, Sweden

Faculty

Rosenquist Brandell, Richard p. 12	Karolinska Institute Stockholm, Sweden
Sanz Buxo, Judit p. 13	Althaia Xarxa Assistencial Universit�ria Manresa Manresa, Spain
Scacciati, Bianca p. 13	Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy.
Sche�l, Anna p. 13	University Hospital Heidelberg, Institute of Pathology Heidelberg, Germany
Sepp�l�, Toni p. 12, 14, 26, 27	Tampere University Tampere, Finland
Siglen, Elen p. 13	Western Norway Familial Cancer Center Bergen, Norway
Silander, Gustav p. 14, 23	Ume� University Ume�, Sweden
Silva, Sofia p. 15	University Hospital A Coru�a A Coru�a, Spain
Silva, Daniela p. 21	University of Porto, Faculty of Medicine Porto, Portugal
Styk, Jakub p. 21	Comenius University Science Park Bratislava, Slovakia
Takabe, Piia p. 18	Tampere University Tampere, Finland
Tang, Alethea p. 12	Swansea Bay University Health Board, Swansea, United Kingdom
Tham, Emma p. 12	Karolinska Institute Stockholm, Sweden
Thelin-Schmidt, Peter p. 25	Uppsala University Uppsala, Sweden

Faculty

Therkildsen, Christina p. 18	Amager og Hvidovre Hospital Copenhagen, Denmark
Usman Babagari, Musa p. 16	Modibbo Adama University Yola Nigeria, Nigeria
van Beekum, Katrin p. 26	University Hospital Bonn, National Center for Hereditary Tumor Syndromes Bonn, Germany
Vermani, Litika p. 19, 22	Cachar Cancer Hospital & Research Centre Silchar, India
Walker, Romy p. 19, 20	University of Melbourne Melbourne, Australia
Walton Bernstedt, Sophie p. 24	Sweden
Wethe, Vibeke p. 19	Oslo University Hospital, Department of Medical Genetics Oslo, Norway
White, Helen p. 19	University of Manchester Manchester, United Kingdom
Willman, Emil p. 24	Sweden
Winship, Ingrid p. 19	Royal Melbourne Hospital Melbourne, Australia
Wollborn, Laura p. 15	Harvard Medical School, Dana-Farber Cancer Institute Boston, MA; USA

Sponsors



**Karolinska
Institutet**

110.800 SEK
(10.000 €)

**RADIUMHEMMETS
FORSKNINGSFONDER**

The Cancer Research Foundations of Radiumhemmet

100000 SEK
(9200 €)



CANCERFONDEN

100000 SEK
(9200 €)

MSInsight
DIAGNOSE BETTER. TREAT SMARTER.

27500 SEK
(2500 €)



2500 £
(2928 €)

SPRINGER NATURE

2 Book-Vouchers
å 250 €



The Event EMT-26-10412 is compliant to the MedTech Europe Code Of Ethical Business Practice.
Event Name: 10th Meeting of the European Hereditary Tumour Group (EHTG)
Dates of the Event: 2026-08-28 to 2026-08-30, City, Country: Stockholm, Sweden

Imprint

Responsible in accordance with press law:

European Hereditary Tumour Group (EHTG) e.V.
Toni Seppälä (Chair)
Weissdornstr. 6
40474 Düsseldorf
toni.seppala@ehtg.org

Organisation:

EHTG secretariat:
Gabriele Sponholz, gs007@ehtg.org



Image Credits

Cover: PantherMedia (now Smartpix)
iStock
Page 9: ERSTA Conference Centre
Page 10: Junibacken



**Thank you for attending
EHTG 2026**



**We look forward to
seeing you next year
in Edinburgh
September 17-19, 2027**

